# Melanotan 2: What the Clinical and Preclinical Research Has Measured

> Melanotan 2, a synthetic cyclic heptapeptide analog of alpha-MSH, has been studied in Phase I human trials, rodent feeding studies, and neuroprotection models. A cited editorial digest.

## What the Melanotan 2 literature has established

Melanotan 2 (MT-II) is a fully synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was designed at the University of Arizona in the early 1990s as a truncated, cyclized, and potency-optimized version of the native 13-amino-acid peptide. The complete sequence is Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2 — a lactam bridge between the Asp5 and Lys10 side chains constrains the backbone into a conformation that binds melanocortin receptors with substantially higher affinity and metabolic stability than linear alpha-MSH.

The research literature on Melanotan 2 spans four primary lines of inquiry: melanogenesis stimulation, erectile function via MC4R, appetite modulation through central melanocortin circuits, and a pharmacovigilance record that documents adverse events in unregulated use. No regulatory agency has approved MT-II for any human indication. The published human data derive from two small early-phase trials — Dorr 1996 (n=3) [1] and Wessells 1998/2000 (n=10–20) [2][3] — and a body of post-market case reports.

The melanogenesis finding came first. In the 1996 Dorr Phase I trial, subcutaneous MT-II at 0.01–0.025 mg/kg produced measurable skin darkening in two of three healthy volunteers within two weeks. [1] The sexual function signal was serendipitous: male subjects in tanning trials reported spontaneous erections, which led to a dedicated MC4R erectile-axis research program. [18] In a double-blind crossover study of 20 men with erectile dysfunction, MT-II at 0.025 mg/kg produced clinically measurable erections in 17 of 20 subjects in the absence of sexual stimulation, with mean tip rigidity exceeding 80% for 41 minutes, compared against placebo. [3]

## Melanotan 2 Tanning Research: Melanogenesis Without UV

The mechanism underlying MT-II's tanning effect is MC1R activation. MC1R is expressed on melanocytes throughout the epidermis; when stimulated by alpha-MSH or its synthetic analogs, MC1R couples to adenylyl cyclase via Gs, elevates intracellular cAMP, activates PKA, and upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis. This pathway drives eumelanin production independent of ultraviolet radiation.

In the 1996 Dorr Phase I study, five low subcutaneous doses administered over ten days produced reflectance-measured pigmentation increases in two of three subjects within two weeks. [1] The 2021 Gilhooley qualitative study of 623 online discussion entries from 205 MT-II users identified cosmetic tanning and fitness competition preparation as the primary stated motivations for use. [7]

MC1R activation can also drive proliferation of melanocytes in individuals with pre-existing dysplastic nevi or melanoma predisposition. Case reports document eruptive dysplastic nevi [20] and histologically confirmed melanoma [9] following MT-II use.

## What Is Melanotan 2?

Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Developed at the University of Arizona under Victor Hruby and Mac Hadley, its molecular weight is 1024.2 Da. MT-II has not been approved for human use by any regulatory authority worldwide.

## What Has Melanotan 2 Been Studied For?

Published research has studied Melanotan 2 for four primary applications: melanogenesis stimulation, erectile dysfunction via MC4R [2][3], appetite and body weight modulation [5][6], and neuroprotection in peripheral nerve injury models. [13] The related compound bremelanotide (PT-141), a direct metabolite of MT-II, received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.

## References

[1] Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. 2000;12 Suppl 4:S74-S79. https://pubmed.ncbi.nlm.nih.gov/11035391/
[5] Cote I et al. Activation of the central melanocortin system chronically reduces body mass. Canadian Journal of Physiology and Pharmacology. 2017;95(2):206-214. https://pubmed.ncbi.nlm.nih.gov/28051332/
[6] Eliason NL et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens. Neuropeptides. 2022;96:102289. https://pubmed.ncbi.nlm.nih.gov/36155088/
[7] Gilhooley E et al. Melanotan II User Experience: A Qualitative Study. Dermatology. 2021;237(6):966-975. https://pubmed.ncbi.nlm.nih.gov/34464955/
[9] Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. https://pubmed.ncbi.nlm.nih.gov/24355990/
[13] Ter Laak MP et al. Melanotan-II promotes peripheral nerve regeneration in the rat. European Journal of Pharmacology. 2003;462(1-3):179-183. https://pubmed.ncbi.nlm.nih.gov/12591111/
[18] Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. https://pubmed.ncbi.nlm.nih.gov/15996790/
[20] Hueso-Gabriel L et al. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012;103(8):740-742. https://pubmed.ncbi.nlm.nih.gov/22425244/

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.